TABLE 2.
Infusion Characteristics (N = 132)
| Criteria | Results |
|---|---|
| Veterans Health Administration COVID-19 Index score, No. (%) | |
| Low risk (0%–8.7%) | 88 (66) |
| Moderate risk (8.8%–16%) | 22 (17) |
| High risk (16.1%–21.2%) | 14 (11) |
| Extreme risk (> 21.3%) | 8 (6) |
|
| |
| Referral type, No. (%) | |
| Infectious disease monoclonal antibody team | 101 (77) |
| Inpatient | 19 (14) |
| Not infectious disease | 12 (9) |
|
| |
| Infusion location, No. (%) | |
| Outpatient | 108 (82) |
| Inpatient | 24 (18) |
|
| |
| Time to infusion, median (range), d | |
| From initial symptom | 6 (0–9) |
| From positive test result | 2 (0–8) |
|
| |
| Monoclonal antibody infusion, No. (%) | |
| Bamlanivimaba | 20 (15) |
| Bamlanivimab-etesevimabb | 12 (9) |
| Casirivimab-imdevimab | 100 (76) |
|
| |
| COVID-19 immunoglobulin G detectedc | 9 (9) |
a
Bamlanivimab Mab infusion therapy was halted on April 16, 2021, due to increased resistance by the COVID-19 viral variant.
b
Bamlanivimab-etesevimab was paused on June 25, 2021, over concerns of reduced susceptibility with the circulating variants of concern.
c
Available for 104 patients.